Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study
- PMID: 22493375
Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study
Erratum in
- Anticancer Res. 2013 Nov;33(11):5211
Abstract
Background: Metastases to the liver receive most of their blood supply from the arterial route, therefore for patients with hepatic metastases from large bowel cancer, hepatic arterial infusion adopting drug-eluting beads preloaded with irinotecan (DEBIRI) may offer a chance of cure.
Patients and methods: In a multi-institutional study, 74 patients were randomly assigned to receive DEBIRI (36) versus systemic irinotecan, fluorouracil and leucovorin (FOLFIRI, 38). The primary end-point was survival; secondary end points were response, recurrence, toxicity, quality of life, cost and influence of molecular markers.
Results: At 50 months, overall survival was significantly longer for patients treated with DEBIRI than for those treated with FOLFIRI (p=0.031, log-rank). Median survival was 22 (95% Confidence Interval CI=21-23) months, for DEBIRI and 15 (95% CI=12-18) months for FOLFIRI. Progression-free survival was 7 (95% CI=3-11) months in the DEBIRI group compared to 4 (95% CI=3-5) months in the FOLFIRI group and the difference between groups was statistically significant (p=0.006, log-rank). Extrahepatic progression had occurred in all patients by the end of the study, at a median time of 13 (95% CI=10-16) months in the DEBIRI group compared to 9 (95% CI 5-13) months in the FOLFIRI group. A statistically significant difference between groups was not observed (p=0.064, log-rank).The median time for duration of improvement to quality of life was 8 (95% CI=3-13) months in the DEBIRI group and 3 (95% CI=2-4) months in the FOLFIRI group. The difference in duration of improvement was statistically significant (p=0.00002, log-rank).
Conclusion: This study showed a statistically significant difference between DEBIRI and FOLFIRI for overall survival (7 months), progression-free survival (3 months) and quality of life (5 months). In addition, a clinically significant improvement in time to extrahepatic progression (4 months) was observed for DEBIRI, a reversal of the expectation for a regional treatment. This suggests a benefit of DEBIRI treatment over standard chemotherapy and serves to establish the expected difference between these two treatment options for planning future large randomized studies.
Similar articles
-
Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study.Ann Surg Oncol. 2011 Jan;18(1):192-8. doi: 10.1245/s10434-010-1288-5. Epub 2010 Aug 26. Ann Surg Oncol. 2011. PMID: 20740319
-
Concomitant capecitabine with hepatic delivery of drug eluting beads in metastatic colorectal cancer.Anticancer Res. 2014 Dec;34(12):7239-45. Anticancer Res. 2014. PMID: 25503155
-
Efficacy and Toxicity of Hepatic Intra-Arterial Drug-Eluting (Irinotecan) Bead (DEBIRI) Therapy in Irinotecan-Refractory Unresectable Colorectal Liver Metastases.World J Surg. 2016 May;40(5):1178-90. doi: 10.1007/s00268-015-3386-9. World J Surg. 2016. PMID: 26711640
-
Transarterial chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: systematic review.J Vasc Interv Radiol. 2013 Aug;24(8):1209-17. doi: 10.1016/j.jvir.2013.05.055. J Vasc Interv Radiol. 2013. PMID: 23885916
-
Intra-arterial therapies for colorectal cancer liver metastases (radioembolization excluded).Bull Cancer. 2017 May;104(5):402-406. doi: 10.1016/j.bulcan.2016.10.025. Epub 2016 Dec 16. Bull Cancer. 2017. PMID: 27993355 Review.
Cited by
-
Consensus statement: the 16th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Saskatoon, Saskatchewan; September 5-6, 2014.Curr Oncol. 2015 Apr;22(2):e113-23. doi: 10.3747/co.22.2362. Curr Oncol. 2015. PMID: 25908916 Free PMC article.
-
Radioembolization as a Treatment Strategy for Metastatic Colorectal Cancer to the Liver: What Can We Learn from the SIRFLOX Trial?Curr Treat Options Oncol. 2016 Jun;17(6):26. doi: 10.1007/s11864-016-0402-8. Curr Treat Options Oncol. 2016. PMID: 27098532 Review.
-
SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018).Clin Transl Oncol. 2019 Jan;21(1):46-54. doi: 10.1007/s12094-018-02002-w. Epub 2018 Dec 18. Clin Transl Oncol. 2019. PMID: 30565083 Free PMC article.
-
Neoadjuvant chemotherapy for colorectal liver metastases: A contemporary review of the literature.World J Gastrointest Oncol. 2021 Sep 15;13(9):1043-1061. doi: 10.4251/wjgo.v13.i9.1043. World J Gastrointest Oncol. 2021. PMID: 34616511 Free PMC article. Review.
-
Strategies for the delay of surgery in the management of resectable hepatobiliary malignancies during the COVID-19 pandemic.Curr Oncol. 2020 Oct;27(5):e501-e511. doi: 10.3747/co.27.6785. Epub 2020 Oct 1. Curr Oncol. 2020. PMID: 33173390 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical